Written question asked by David Anderson (Labour) on Wednesday, 3 February 2016, in the House of Commons. It was due for an answer on Friday, 5 February 2016. It was answered by George Freeman (Conservative) on Tuesday, 9 February 2016 on behalf of the Department of Health.
Muscular Dystrophy: Drugs
- Question
-
To ask the Secretary of State for Health, what steps he is taking to make translarna available to boys who could benefit from it.
- Answer
-
The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance for the National Health Service on whether to fund selected drugs and treatments. NICE is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The publication date for NICE’s final guidance is to be confirmed.
The NHS in England is legally required to fund drugs and treatments recommended in NICE highly specialised technology guidance within three months of its final guidance being issued. In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund medicines based on an assessment of the available evidence.
Secondary information
- Type
- Written question
- Reference
- 25696
- Session
- 2015-16
- Subjects
- Drugs Muscular dystrophy Ataluren Boys
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-01-27 14:38:45 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/25696
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/25696
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/25696